Analysis of SDHD promoter mutations in various types of melanoma

Scholz SL, Horn S, Murali R, Möller I, Sucker A, Sondermann W, Stiller M, Schilling B, Livingstone E, Zimmer L, Reis H, Metz CH, Zeschnigk M, Paschen A, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG (2015)

Publication Type: Journal article

Publication year: 2015

Journal

Oncotarget Impact Journals

Book Volume: 6

Pages Range: 25868-25882

Journal Issue: 28

DOI: 10.18632/oncotarget.4665

Abstract

Objectives: Recently, recurrent mutations in regulatory DNA regions, such as promoter mutations in the TERT gene were identified in melanoma. Subsequently, Weinhold et al. reported SDHD promoter mutations occurring in 10% of melanomas and being associated with a lower overall survival rate. Our study analyzes the mutation rate and clinico-pathologic associations of SDHD promoter mutations in a large cohort of different melanoma subtypes. Methods: 451 melanoma samples (incl. 223 non-acral cutaneous, 38 acral, 33 mucosal, 43 occult, 43 conjunctival and 51 uveal melanoma) were analyzed for the presence of SDHD promoter mutations by Sanger-sequencing. Statistical analysis was performed to screen for potential correlations of SDHD promoter mutation status with various clinico-pathologic criteria. Results: The SDHD promoter was successfully sequenced in 451 tumor samples. ETS binding site changing SDHD promoter mutations were identified in 16 (4%) samples, of which 5 mutations had not been described previously. Additionally, 5 point mutations not located in ETS binding elements were identified. Mutations in UV-exposed tumors were frequently C>T. One germline C>A SDHD promoter mutation was identified. No statistically significant associations between SDHD promoter mutation status and various clinico-pathologic variables or overall patient survival were observed. Conclusions: Melanomas harbor recurrent SDHD promoter mutations, which occur primarily as C>T alterations in UV-exposed melanomas. In contrast to the initial report and promoter mutations in the TERT gene, our analysis suggests that SDHD promoter mutations are a relatively rare event in melanoma (4% of tumors) of unclear clinical and prognostic relevance.

Involved external institutions

Universitätsklinikum Essen DE Germany (DE) Memorial Sloan Kettering Cancer Center US United States (USA) (US)

How to cite

APA:

Scholz, S.L., Horn, S., Murali, R., Möller, I., Sucker, A., Sondermann, W.,... Griewank, K.G. (2015). Analysis of SDHD promoter mutations in various types of melanoma. Oncotarget, 6(28), 25868-25882. https://doi.org/10.18632/oncotarget.4665

MLA:

Scholz, Simone L., et al. "Analysis of SDHD promoter mutations in various types of melanoma." Oncotarget 6.28 (2015): 25868-25882.

BibTeX: Download